LQDA vs MAIN Comparison

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Main Street Capital Corp is a principal investment firm focused on providing customized long-term debt and equity capital solutions to lower middle market ("LMM") companies and debt capital to private ("Private Loan") companies owned by or in the process of being acquired by a private equity fund. The group invests principally in secured debt investments, equity investments, warrants, and other securities of LMM companies, typically based in the U.S. The company operates as a single segment with a principal investment objective to maximize total return by generating current income from debt investments and current income and capital appreciation from equity and equity-related investments.